Supplementary Figure S4 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression Yazar: Chuandong Geng (17315310)

Konular:

Supplementary Table S5 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression Yazar: Chuandong Geng (17315310)

Konular:

Supplementary Figure S3 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression Yazar: Chuandong Geng (17315310)

Konular:

Supplementary Figure S8 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression Yazar: Chuandong Geng (17315310)

Konular:

Supplementary Figure S5 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression Yazar: Chuandong Geng (17315310)

Konular:

Supplementary Table S2 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML Yazar: Christopher T. Letson (16424095)

Konular:

Figure 1 from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma Yazar: Marianna Carrabotta (8193039)

Konular:

Figure 4 from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma Yazar: Marianna Carrabotta (8193039)

Konular:

Figure 2 from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma Yazar: Marianna Carrabotta (8193039)

Konular:

Figure 5 from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma Yazar: Marianna Carrabotta (8193039)

Konular:

Table 1 from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma Yazar: Marianna Carrabotta (8193039)

Konular:

Figure 3 from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma Yazar: Marianna Carrabotta (8193039)

Konular:

Supplementary Table S9 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor The... Yazar: Anfal Alsadhan (15907475)

Konular:

Figure S4 from Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy Yazar: Alexander J. Cole (14971167)

Konular:

Supplementary Table S7 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor The... Yazar: Anfal Alsadhan (15907475)

Konular:

Figure S3 from Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy Yazar: Alexander J. Cole (14971167)

Konular:

Figure S5 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition Yazar: Upendra Kumar Soni (15051683)

Konular:

Figure S1 from Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy Yazar: Alexander J. Cole (14971167)

Konular:

Figure S2 from Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy Yazar: Alexander J. Cole (14971167)

Konular:

Figure S4 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition Yazar: Upendra Kumar Soni (15051683)

Konular: